INDVIndivior Pharmaceuticals, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Price is +1% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 1.1% since the previous count, down from 9.2% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How INDV is trading
Indivior Pharmaceuticals, Inc. is +59% over the past year while the S&P 500 is +18%: 41 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +1.1%
vs 200-day average · close to trend
- RSI (14)
- 52
RSI (14) · neutral
- Below its 52-week high
- 14%
Below its 52-week high
Details›
- Last close2026-10-09
- $35.84
- 1 monthS&P 500 +2.7%
- +3.9%
- 1 yearS&P 500 +18%
- +59%
- 5 yearsS&P 500 +88%
- +157%
- vs 50-day average$36.49
- −1.8%
- 52-week high
- $41.47
- 52-week low
- $22.73
- Annualised volatility
- 48%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $108K
| Year | Return |
|---|---|
| 2026 (year to date) | −0.11% |
| 2025 | +189% |
| 2024 | −19% |
| 2023 | −30% |
| 2022 | +26% |
| 2021 | +135% |
| 2020 | +182% |
| 2019 | −61% |
| 2018 | −75% |
| 2017 | +55% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +3.8% |
| Feb | 10 | 5 of 10 | +0.24% |
| Mar | 10 | 4 of 10 | −1.3% |
| Apr | 10 | 8 of 10 | +2.8% |
| May | 10 | 8 of 10 | +5.6% |
| Jun | 10 | 4 of 10 | +3.6% |
| Jul | 11 | 7 of 11 | +13% |
| Aug | 11 | 6 of 11 | +0.35% |
| Sep | 11 | 3 of 11 | −9.4% |
| Oct | 11 | 4 of 11 | +4.0% |
| Nov | 10 | 6 of 10 | −0.94% |
| Dec | 10 | 7 of 10 | +2.8% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #1 of 41 by RyuScore